Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a ghrelin mimetic
Weight loss was significant in outcome trials, ranging from a 0.6 kg reduction at 12 weeks in the ELIXA trial to a 4.3 kg reduction at 2 years with injectable semaglutide in the SUSTAIN-6 trial
[7-9] For sitagliptin, no differences in cardiac events were observed compared with placebo in an analysis of 5,429 patients, [7] and similar results were found for vildagliptin against all comparators in data from 7,509 patients
placebo 30%, risk difference = 25, 95% CI = 546)
The other above-mentioned global SURMOUNT studies are still ongoing, in SURMOUNT-2, 938 participants with T2D are enrolled receiving either 10 or 15 mg of tirzepatide